Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Core Viewpoint - Gain Therapeutics, Inc. is actively participating in key healthcare conferences to showcase its advancements in allosteric small molecule therapies, particularly focusing on its lead drug candidate GT-02287 for Parkinson's disease [1][2]. Conference Participation - Gain Therapeutics will attend the 44th Annual J.P. Morgan Healthcare Conference and other related events, including the Sachs Neuroscience Innovation Forum on January 11, 2026, and the Demy-Colton/Informa Biotech Showcase from January 12-14, 2026 [1][3]. - The company will conduct presentations and one-on-one meetings with management during these events, providing opportunities for investors and stakeholders to engage directly [3][4]. Drug Development - GT-02287 is in clinical development for treating Parkinson's disease, targeting both patients with and without a GBA1 mutation [5][8]. - The drug functions as an allosteric enzyme modulator, aiming to restore the function of the glucocerebrosidase enzyme, which is often impaired due to genetic mutations or age-related stress [5]. - In preclinical models, GT-02287 has shown promising results, including restoration of enzymatic function and reduction of neurodegeneration biomarkers [5][6]. Clinical Trials - GT-02287 is currently undergoing a Phase 1b clinical trial across seven sites in Australia, focusing on safety and tolerability over a three-month period [6]. - An extension of the Phase 1b study allows participants to continue treatment for up to 12 months, indicating a commitment to long-term evaluation of the drug's effects [6]. Funding and Support - The development of GT-02287 has received funding from notable organizations, including The Michael J. Fox Foundation and the Eurostars-2 program, highlighting the drug's potential and the support it has garnered [7]. Company Overview - Gain Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of next-generation allosteric therapies, with a focus on neurodegenerative diseases and other challenging disorders [8][10]. - The company employs its proprietary Magellan™ platform to accelerate drug discovery and develop novel treatments for various conditions, including lysosomal storage disorders and solid tumors [10].